Fig. 1 · Structure

Documents & Downloads

Ropinirole HCl

Cat. No. A11916 CAS 91374-20-8
Ropinirole Hydrochloride is a dopamine receptor agonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
D2 receptor Ki 29 nM

Ropinirole HCl Research Summary

This section summarizes 2 in vivo studies of Ropinirole HCl from 1 published reference.

Ropinirole HCl In Vivo Studies

In adult female Sprague-Dawley rats with sham lesions, Ropinirole administered via s.c. injections increased distance travelled in the open field test compared with saline and LD24. Ropinirole also increased the fraction of time in the inner zone relative to both L-DOPA and saline. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Ropinirole increases open field distance travelled in sham-lesioned rats

Animal study · Adult female Sprague-Dawley rats; sham lesions; nsham = 9 [1]

Treatment with ropinirole induced a large increase in distance travelled in both sham-lesioned and 6-OHDA-lesioned rats. During the EPM test, ropinirole did not induce an increase in the total distance travelled as seen in the open field test, but instead reduced the distance travelled compared with both L-DOPA and vehicle treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
distance travelleddistance travelled >20-fold increase[1]

Conditions shared by the study groups

Route
s.c. injections
Treatment course
daily; five consecutive days (day 1 to day 5) with a drug-free period of two days (days 6 and 7) for a total of 6 weeks; open field test during treatment week 2; 15 min before the beginning of each behavioural test
Vehicle
physiological saline solution
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ropinirole 2.5 mg/kgsaline and LD24ropinirole 2.5 mg/kg (R2.5); sham-lesioned rats; open field test during treatment week 2: >20-fold increase vs saline and LD24, p < 0.05[1]
Ropinirole 2.5 mg/kg
Model: Adult female Sprague-Dawley rats; sham lesions; nsham = 9
Methods and source locations

Compound reported in the paper: Ropinirole

The paper names Ropinirole without stating the salt or form; not verified as the hydrochloride form supplied as A11916. No dose conversion or lot validation.

Results > Evaluation of the 6-OHDA lesion and motor effects of the treatments (S6); Results > Ropinirole, but not L-DOPA, induced hyperactivity with signs of reduced anxiety (S22); Methods > Animals (S136); Methods > Study design (S138, S139, S141); Methods > Drug treatments (S146, S149); Methods > Bilateral dopamine-denervating lesions (S158)

distance travelled: distance travelled; comparator: saline and LD24 — Results > Ropinirole, but not L-DOPA, induced hyperactivity with signs of reduced anxiety (S22); Methods > Study design (S138, S141)

Ropinirole 2.5 mg/kg · Results > Ropinirole, but not L-DOPA, induced hyperactivity with signs of reduced anxiety (S22); Methods > Study design (S138, S139, S141); Methods > Drug treatments (S149)

Ropinirole and inner-zone time in sham-lesioned rats

Animal study · Adult female Sprague-Dawley rats; sham lesions; nsham = 9 [1]

Adult female Sprague-Dawley rats with sham lesions received Ropinirole via s.c. injections. In the open field test, Ropinirole increased the fraction of time in the inner zone relative to both L-DOPA and saline.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
fraction of time in the inner zonefraction of time in the inner zone approximately four-fold[1]

Conditions shared by the study groups

Route
s.c. injections
Treatment course
daily; five consecutive days (day 1 to day 5) with a drug-free period of two days (days 6 and 7) for a total of 6 weeks; open field test during treatment week 2; 15 min before the beginning of each behavioural test
Vehicle
physiological saline solution
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ropinirole 2.5 mg/kgL-DOPA and salineropinirole 2.5 mg/kg (R2.5); sham lesions; open field test during treatment week 2: increased the fraction of time in the inner zone approximately four-fold relative to both L-DOPA and saline; p < 0.05[1]
Ropinirole 2.5 mg/kg
Model: Adult female Sprague-Dawley rats; sham lesions; nsham = 9
Methods and source locations

Compound reported in the paper: Ropinirole

The paper names Ropinirole without stating the salt or form; not verified as the hydrochloride form supplied as A11916. No dose conversion or lot validation.

Results > Evaluation of the 6-OHDA lesion and motor effects of the treatments (S6); Results > Ropinirole, but not L-DOPA, induced hyperactivity with signs of reduced anxiety (S27); Methods > Animals (S136); Methods > Study design (S138, S139, S141); Methods > Drug treatments (S146, S149); Methods > Bilateral dopamine-denervating lesions (S158)

fraction of time in the inner zone: fraction of time in the inner zone; comparator: L-DOPA and saline — Results > Ropinirole, but not L-DOPA, induced hyperactivity with signs of reduced anxiety (S27); Methods > Study design (S138, S141)

Ropinirole 2.5 mg/kg · Results > Ropinirole, but not L-DOPA, induced hyperactivity with signs of reduced anxiety (S27); Methods > Study design (S138, S139, S141); Methods > Drug treatments (S149)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 91374-20-8
Formula C16H24N2O HCl
Molecular Weight 296.84
SMILES
CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 9 mg/mL (30.31 mM)
Water 52 mg/mL (175.17 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ropinirole HCl Research References

  1. [1] Wolfschlag M, Espa E, Skovgård K, et al. Impulsive-compulsive behaviours and striatal neuroactivity in mildly parkinsonian rats under D2/3 agonist and L-DOPA treatment. NPJ Parkinsons Dis (2025). PMID: 40442152 DOI: 10.1038/s41531-025-00996-z Source material

Added to your cart

View Cart Checkout
Loading...